详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

High expression of UBE2T predicts poor prognosis and survival in multiple myeloma

文献详情

资源类型：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, 100191 Beijing, China [2]Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC 3010, Australia [3]Department of Respiratory Medicine, The First Affiliated Hospital of Gannan Medical University, 341000 Ganzhou, China [4]Department of Pathology, Beijing Tiantan Hospital Affiliated with Capital Medical University, No. 6 Tiantan Xili, 100050 Beijing, China

出处：

DOI：

ISSN：

摘要：

Multiple myeloma (MM) is one of hematological malignancies, characterized by malignant proliferation of plasma cells. Biomarkers play an important role in evaluating the development and prognosis of MM. Ubiquitin-conjugating enzyme E2T (UBE2T) is served to connect with particular E3 ubiquitin ligase to degraded-related substrates, contributing to DNA repair in the Fanconi anemia pathway. Also, numerous evidences reported that UBE2T is closely related to cell proliferation and carcinogenesis. However, the relationship between MM and UBE2T has not been studied. Here, we integrated eight datasets and analyzed the relationship of expression of UBE2T and ISS, 1q21, relapse and survival in MM 2684 patients (totally 2893 samples). We found that the expression of UBE2T increased with the deterioration of MM (P = 1.4e-07), especially in the early stage. UBE2T is closely related to IgG serotype MM (P = 6.9e-05). High expression of UBE2T is associated with poor survival and prognosis (EFS: P = 1.43e-03, OS: P = 5.47e-05). UBE2T is likely to play a part in the cell division pathway, affecting the survival and prognosis of MM. Therefore, UBE2T could be considered as an early alternative biomarker for the prognosis of MM. © 2019, The Author(s).

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 2 区医学

小类 | 3 区生物工程与应用微生物 3 区遗传学 3 区医学：研究与实验 3 区肿瘤学

最新[2023]版：

大类 | 3 区医学

小类 | 2 区生物工程与应用微生物 3 区遗传学 3 区医学：研究与实验 4 区肿瘤学

JCR分区：

出版当年[2017]版：

Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q1 GENETICS & HEREDITY Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q2 ONCOLOGY

最新[2023]版：

Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q1 GENETICS & HEREDITY Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 ONCOLOGY

影响因子： 4.8 最新[2023版] 4.9 最新五年平均 4.044 出版当年[2017版] 3.008 出版当年五年平均 3.652 出版前一年[2016版] 4.681 出版后一年[2018版]

第一作者：

第一作者机构： [1]Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, 100191 Beijing, China

共同第一作者：

通讯作者：

通讯机构： [1]Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, 100191 Beijing, China [4]Department of Pathology, Beijing Tiantan Hospital Affiliated with Capital Medical University, No. 6 Tiantan Xili, 100050 Beijing, China

推荐引用方式(GB/T 7714)：

APA：

MLA：